- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04181957
Effects of LDX on Cognitive Processes and Appetite
The Effects of Lisdexamfetamine Dimesylate on Cognitive, Metabolic, and Reward Processes in Individuals With Binge-eating Symptoms
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Birmingham, United Kingdom, B152TT
- University of Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Fluent English speakers
- Be willing to be informed of chance pathological findings from the fMRI scan
- Must have binge-eating symptoms that is measured by a minimum score of 18 on the Binge Eating Scale
- Must have a minimum BMI of 18.5
- Must be below 152.4kg
- Must have clearance from a qualified physician before participating
Exclusion Criteria:
Symptoms or diagnosis of other eating disorders.
- Psychotherapy and/or pharmacotherapy for binge-eating disorder (BED) 3 months before the study, as this will suggest a diagnosis of BED and may influence eating behaviour.
- Metabolic (e.g. metabolic disorder, diabetes), psychological (e.g. depression), substance, or neurological (e.g. epilepsy, headache disorder, multiple sclerosis, traumatic brain injuries) diseases or medication in relation to these diseases
- Intake of any medication that can interfere with the drug or measurements, determined through questionnaires in the screening session
- Current smoking, as it can interfere with appetite
- Current pregnancy or breastfeeding
- Not passing a breathalyser test on the morning of testing.
- Food allergies (e.g. peanut allergy, lactose and gluten intolerance) or vegetarian/vegan diet
- Disliking the study lunch to ensure that participants will consume the provided food
- Women will be asked to participate only in weeks when they are not menstruating or in their pre-menstrual week, to avoid hormonal disruption to appetite.
The following are exclusion criteria are specific to the MRI scanner:
- Non-removable metal object in or on their body, such as: heart pace-maker, artificial heart valve, metal prosthesis, implants or splinters, non-removable dental braces
- Left-handed
- Tattoos that are older than 10 years
- Claustrophobia
- Limited temperature perception and/or increased sensitivity to warming of the body
- Pathological hearing ability or an increased sensitivity to loud noises
- Operation less than three months ago
- Simultaneous participation in other studies that involve drug intake or blood sampling
- Acute illness or infection during the last 4 weeks
- Cardiovascular disorders (e.g., hypertrophic cardiomyopathy, long QT syndrome) to ensure medical fitness to participate
- Moderate or severe head injury
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants receive placebo tablet composed of lactose.
|
Participants take one dose of placebo (lactose) tablet.
|
Active Comparator: Active
Participants receive a 50mg tablet of lisdexamfetamine dimesylate (LDX) once.
|
Participants take one 50mg tablet of lisdexamfetamine dimesylate once.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metabolic food intake
Time Frame: 15 minutes
|
We will examine if LDX has an influence on metabolic food intake using a lab-based food task, in which participants eat as much pasta as they like until they feel comfortably full .
Amount eaten will be measured in grams.
|
15 minutes
|
Hedonic food intake
Time Frame: 15 minutes
|
The effect of LDX on hedonic food intake will be measured via offering a palatable snack of chocolate chip cookies 20 minutes after participants have consumed the pasta.
Amount eaten will be measured in grams.
|
15 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
fMRI Reward Processes
Time Frame: 21 minutes
|
We will investigate the effect of LDX on neural responses to food stimuli using fMRI, and if/how liking ratings modulate these responses.
The participants will perform a food and non-food rating task in the scanner, to measure reward-responses.
Participants will view a range (36 each category) of high -and low-calorie food (equally distributed in sweet and savoury), and non-food items (visually matched).
All items will be scored for appealing/liking with the use of a button box, varying from 1 (not at all) to 5 (very much).
Each item will be presented for 3000ms followed by a fixation cross (500 - 1500ms).
(3 x 7 min = 21 min)
|
21 minutes
|
Ratings
Time Frame: 20 minutes
|
We will determine if LDX administration has an effect on appetite and mood ratings via a visual analogue scale (VAS) in a hungry and sated state.
Participants will drag a cursor from 0cm (not at all) to 10cm (most I could imagine) to self-report mood and appetite.
|
20 minutes
|
Emotional processing
Time Frame: 35 minutes
|
We will determine if LDX modulates emotional processing. The ETB is a computerised battery that comprises the following tasks: FERT: Faces will appear on a screen ranging in emotions. The participant is instructed to classify each expression as quickly and accurately as possible. Accuracy, response bias, reaction time, and target sensitivity. ECAT: 60 positive and negative adjectives will be presented for the participant to indicate if they would like to be described as such. Accuracy and reaction times. EREC: The participants will be asked to recall as many words from the ECAT as can be remembered within a 4-minute period. The number of correct words recalled and respective valence will be measured. EMEM: Participants will be presented with personality descriptors derived from the ECAT, along with matching novel distractor words. Participants will indicate if the descriptor was presented before. Accuracy, reaction time, response bias, and target sensitivity. |
35 minutes
|
Memory
Time Frame: 10 minutes
|
We will investigate the effect of LDX on working memory.
To assess working memory and working memory capacity, participants will complete a visuospatial n-back task.
The participant is presented with a sequence of circles on a 3x3 grid.
The participant is instructed to indicate whether the current circle location matches the location of the circle n trials earlier.
In this design, participants will identify if the circle matches the circle 2 and 3 trials back on separate cycles.
Participants will complete 70 trials of each n-back condition.
This task takes approximately 10 minutes to complete.
|
10 minutes
|
Attention
Time Frame: 14 minutes
|
We will investigate the effect of LDX on attention.
This task is a series of white letters presented on a grey background in random order, modelled on the Conner's Continuous Performance Task.
Participants are instructed to press the space bar for every letter except 'X'.
Letters will be presented for 900ms.
Accuracy and reaction time will be measured.
The task duration is 14 minutes.
|
14 minutes
|
Cognitive inhibition/Impulsivity
Time Frame: 10 minutes
|
We will investigate LDX effect on cognitive control (ie inhibition).
Participants will complete the delay-discounting task for money and food.
The delay-discounting task measures the extent to which participants are willing to delay the receipt of a reward, in exchange for receiving a higher-value reward, and is generally considered to reflect impulsive behaviour.
This task is a monetary discounting task with nine delays ranging from one day to one year.
On a screen, participants see the question 'Which would you prefer?', with two choices: £xx now or £xx after a delay (varying from one day to one year), and will be asked to choose between the two.
A similar paradigm will be used for food, with questions consisting of food variables instead of money.
Questions will require a choice between a smaller amount of food now, and a larger amount later.
Area under the curve will be calculated.
|
10 minutes
|
Motor inhibition/Impulsivity
Time Frame: 10 minutes
|
We will measure the effect of LDX on inhibition using the Stop Signal Task.
The stop signal task requires the participant to identify the direction of a circle's location on the screen (i.e., left or right).
If, however, the circle is encased in another circle, then the participant is to withhold a response.
Successful inhibition, commission errors, and reaction time will be measured.
|
10 minutes
|
fMRI food reward - activation
Time Frame: 21 minutes
|
We will investigate the activation changes in brain regions associated with reward to food when viewing pictures of food. When assessing changes in activation we will assess how activity in separate brain regions changes when attending to food pictures compared to when attending to visually-matched non-food pictures. |
21 minutes
|
fMRI food reward - functional connectivity
Time Frame: 21 minutes
|
We will investigate the changes in functional connectivity between brain regions associated with reward to food when viewing pictures of food. When looking at changes in functional connectivity we will assess how the relationship between activity in any two or more brain regions is altered when attending to food pictures compared to when attending to visually-matched non-food pictures. |
21 minutes
|
fMRI inhibition - activation
Time Frame: 18 minutes
|
We will investigate the effect of LDX on brain regions associated with cognitive control, during performance of a delay discounting task (Outcome 8).
When assessing changes in activation we will assess how activity in separate brain regions changes when making decisions about food compared to when making decisions about money.
|
18 minutes
|
fMRI inhibition - functional connectivity
Time Frame: 18 minutes
|
We will investigate the changes in functional connectivity between brain regions associated with cognitive control. When looking at changes in functional connectivity we will assess how the relationship between activity in any two or more brain regions is altered when making decisions about food compared to when making decisions about money. |
18 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Suzanne Higgs, PhD, University of Birmingham
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Signs and Symptoms, Digestive
- Feeding and Eating Disorders
- Hyperphagia
- Bulimia
- Binge-Eating Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Lisdexamfetamine Dimesylate
Other Study ID Numbers
- IRAS 250510
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Binge Eating
-
Lindner Center of HOPEUniversity of CincinnatiCompleted
-
ShireCompleted
-
University of North Carolina, Chapel HillThe Hilda & Preston Davis Foundation; Global Foundation for Eating DisordersCompletedEating Disorder | Binge-eating DisorderUnited States
-
Sao Jose do Rio Preto Medical SchoolFundação de Amparo à Pesquisa do Estado de São PauloCompletedBinge-Eating Disorder | Eating Disorders | Eating Behavior | Eating Disorder | Binge Eating Disorder Associated With ObesityBrazil
-
Otsuka Pharmaceutical Development & Commercialization...CompletedBinge-Eating DisorderUnited States
-
TRYP TherapeuticsActive, not recruitingBinge Eating DisorderUnited States
-
King's College LondonActive, not recruitingBinge-Eating DisorderUnited Kingdom
-
ShireCompletedBinge Eating DisorderUnited States
-
ShireCompletedBinge Eating DisorderSpain, United States, Germany
-
SunovionCompleted
Clinical Trials on Placebo oral tablet
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
EicOsis Human Health Inc.RecruitingHealthy SubjectsNew Zealand
-
Harmony Biosciences, LLCActive, not recruitingMyotonic Dystrophy 1 | Excessive Daytime SleepinessUnited States, Canada
-
Syntrix Biosystems, Inc.National Institute on Drug Abuse (NIDA); DF/Net ResearchCompletedDiabetic Neuropathies | Neuropathic Pain | Pain, ChronicUnited States
-
University of OxfordNovo Nordisk A/SRecruitingDiabetes Mellitus, Type 2United Kingdom
-
Fulcrum TherapeuticsTerminated
-
EicOsis Human Health Inc.CompletedHealthy AdultsUnited States
-
The Mind Research NetworkTerminatedSmoking Cessation | Tobacco Use DisorderUnited States
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Sunshine Lake Pharma Co., Ltd.CompletedChronic Hepatitis CChina